First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

por Van Cutsem, E., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne-Jones, R., Punt, C. J. A., Van de Wouw, A. J., Fedyanin, M., Stroyakovskiy, D., Kroening, H., Garcia-Alfonso, P., Wasan, H., Falcone, A., Fougeray, R., Egorov, A., Amellal, N., Moiseyenko, V.
Publicado 2022